Protocol Ledger

NCT04308395 · Phase III · TERMINATED

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Interventional Phase III clinical trial protocol NCT04308395 sponsored by Sol-Gel Technologies in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-03 Enrollment: 108 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04308395
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)108 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04308395
Protocol FieldVerified Registry Value
NCT IdentifierNCT04308395
Consolidated Lead SponsorSol-Gel Technologies
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment108 participants (ACTUAL)
Registered Start Date2020-06-03
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI